Go to the list of all blogs
Alicia's Avatar
published in Blogs
May 20, 2026
Why Is Nanobiotix S.A. (NBTX) Stock Down -8% Today?

Why Is Nanobiotix S.A. (NBTX) Stock Down -8% Today?

Key Takeaways

  • NBTX shares fell approximately 8.09% to $42.47 from the prior session close of $46.20.
  • The decline followed recent positive clinical updates and appears driven by profit-taking in a high-volatility biotech name.
  • No major new company-specific news emerged on the session to explain the move.
  • Broader biotech sector showed mixed performance while major indices traded modestly lower.
  • Traders are monitoring upcoming data readouts and any follow-through volume for signs of stabilization.

What Happened With NBTX Shares Today

Nanobiotix S.A. (NBTX), a late-stage clinical biotechnology company focused on nanoparticle-based therapies to enhance cancer treatments, saw its shares decline sharply in today’s session. The stock dropped roughly 8.09% to close near $42.47 after finishing the previous session at $46.20. The move occurred without fresh fundamental announcements and reflected typical post-rally consolidation in a volatile biotech stock.

Profit-Taking After Recent Gains

NBTX had rallied strongly in prior sessions on encouraging Phase 2 data for its lead candidate JNJ-1900 (NBTXR3) in inoperable lung cancer. With those gains in place, investors took profits, producing the intraday reversal. The absence of new catalysts left the stock exposed to normal rotation out of recent winners.

Market Context and Trading Activity

Volume remained elevated relative to the recent average, consistent with heightened interest following the prior week’s clinical news. The move diverged modestly from broader biotech peers and sector ETFs, which finished mixed. No major technical support levels were decisively breached, though the stock pulled back from near-term highs reached earlier in the week. I checked comparable names in the space using Tickeron’s AI tools to see how this action compared to peers.

Reviewing AI Trading Insights for Context

In my analysis of volatile names like this one, I find it helpful to look at how automated strategies are performing across similar tickers. Tickeron’s Trending AI Robots page highlights the strongest-performing AI trading bots under current market conditions. The platform offers hundreds of bots across thousands of tickers, each built around distinct strategies, timeframes, and performance metrics. Only those demonstrating superior results in the prevailing environment appear in the curated section. Investors can explore the page to review active bots and their historical results.

What Comes Next for NBTX

Attention now turns to additional data readouts from ongoing trials and any updates on the company’s regulatory timeline. Analysts continue to focus on progress with the pivotal head-and-neck cancer program and potential partnership developments. As with any clinical-stage biotech, volatility is expected around news events and broader sector sentiment. I’m watching this closely for signs of stabilization in the coming sessions.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NBTX

Momentum Indicator for NBTX turns positive, indicating new upward trend

NBTX saw its Momentum Indicator move above the 0 level on June 23, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned positive. In of the 100 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in of 226 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 52 cases where NBTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NBTX turned negative on May 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

NBTX moved below its 50-day moving average on June 02, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NBTX crossed bearishly below the 50-day moving average on June 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NBTX entered a downward trend on June 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (20.978). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). NBTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (49.505) is also within normal values, averaging (367.072).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.06B. The market cap for tickers in the group ranges from 58 to 121.87B. VRTX holds the highest valuation in this group at 121.87B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 6%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 1,797%. NVCT experienced the highest price growth at 102%, while CRIS experienced the biggest fall at -52%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -51%. For the same stocks of the Industry, the average monthly volume growth was -25% and the average quarterly volume growth was 129%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 55
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
NBTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
60 Rue de Wattignies
Phone
+33 140260470
Employees
97
Web
https://www.nanobiotix.com
Interact to see
Advertisement
In the ever-shifting healthcare sector, CVS Health (CVS) and UnitedHealth Group (UNH) represent two powerhouse approaches: CVS as a retail pharmacy giant with integrated insurance and services, and UNH as a leading health insurer with diversified operations.
In the competitive retail landscape, American Eagle Outfitters (NYSE: AEO) is showing signs of robust upward potential as it navigates a strong 2025 performance.
In the dynamic world of satellite communications and broadband services, EchoStar Corporation (NASDAQ: SATS) has captured investor attention with a notable technical breakthrough. On December 8, 2025, the stock's 10-day moving average crossed above its 50-day moving average, signaling the onset of a bullish upward trend.
In an era where global investors demand instant access to markets, major players in the financial world are racing to extend trading hours beyond the traditional 9:30 a.m. to 4 p.m. ET window. This push is driven by surging foreign holdings of U.S. equities, which hit $17 trillion last year, and the growing appetite for nonstop trading in a 24/7 digital economy.
In the resilient gold mining sector, IAMGOLD Corporation (NYSE: IAG) has demonstrated an extraordinary uptrend throughout 2025, capitalizing on rising gold prices and operational milestones.
Within the rapidly evolving automotive retail landscape, Carvana Co. (NYSE: CVNA) has emerged as one of 2025’s standout performers. Once viewed as a highly volatile name, the company has transformed into a market leader as demand for online vehicle purchasing accelerates
Microsoft (MSFT) emerges as the AI-favored stock in 2025, outperforming Apple (AAPL) with a 16% year-to-date gain, compared to Apple’s 10% rise. The advantage stems from Microsoft’s deeper enterprise AI integration, accelerating cloud growth, and scalable software ecosystem.
ExxonMobil (XOM) emerges as the AI-preferred energy stock in 2025, posting a 10% year-to-date gain compared with Chevron’s (CVX) 2% increase. Stronger upstream production, exposure to high-growth assets, and expanding low-carbon initiatives support XOM’s momentum. Tickeron’s AI models signal continued upside for XOM, while CVX shows signs of overbought conditions and elevated downside risk.
Tesla (TSLA) emerges as the AI-preferred EV stock in 2025, posting a 19% year-to-date gain, while BYD (BYDDY) has declined 82%, reflecting diverging momentum across the global EV market. Tickeron’s AI trading bots indicate strong bullish conditions for TSLA, supported by positive momentum signals, whereas BYDDY shows sustained bearish trends.
Broadcom (AVGO) emerges as the AI-preferred semiconductor stock in 2025, posting a 48% year-to-date gain, compared with 37% for NVIDIA (NVDA), supported by stronger diversification across networking, infrastructure, and custom AI chips.
- Bio-Techne carries a “Moderate Buy” consensus from 13 analysts, with an average price target of $70.58, implying about 15% upside. - Recent positive revisions include TD Cowen (Oct. 14, target raised from $65 to $70, Strong Buy), Evercore ISI (Oct. 7, $60 to $72, Buy), and RBC -
Skyworks Solutions (SWKS) has traded unevenly in recent weeks as investors digest shifting sector dynamics and company-specific guidance. The stock has moved into a consolidation phase following broader semiconductor rotations, with optimism in diversified end markets offset by ongoing pressure in mobile.
Seagate Technology (STX) has emerged as one of the standout performers of 2025, powered by explosive demand for data storage tied to artificial intelligence workloads. As hyperscalers expand cloud and AI infrastructure, Seagate’s high-capacity hard drives have become essential, pushing the stock sharply higher and keeping investor attention firmly locked on upcoming earnings.
Home Depot and Lowe’s are the two dominant players in the home improvement retail space, frequently compared due to their similar product offerings and overlapping customer bases of DIY homeowners and professional contractors. Their performance is closely watched as a barometer for consumer discretionary spending, housing market trends, and interest rate impacts.
Over the past month, Wynn’s share price has been shaped by a combination of analyst actions, expansion-related news, and shifting industry dynamics. The stock reached a 52-week high in early December, supported by positive premarket activity and renewed optimism across consumer-facing sectors.
Visa (V) strengthened its leadership in global payments, advancing AI-driven tools, stablecoin advisory services, and enhanced security offerings in 2025.
Goldman Sachs and Morgan Stanley are leading global investment banks, frequently compared due to their overlapping operations in capital markets, wealth management, and advisory services. Evaluating these stocks side by side helps investors and traders understand differences in risk, growth potential, and revenue drivers amid ongoing macroeconomic shifts, tariff impacts, and a resurgence in deal-making activity.
Equinox Gold (EQX) and Coeur Mining (CDE) are notable players in the precious metals mining sector, focusing on gold and silver production in a market influenced by economic uncertainty, inflation hedges, and global demand. This comparison provides insight for investors tracking commodity trends or seeking safe-haven assets.
Strategic Acquisitions and Expansion: USAR acquired UK-based Less Common Metals, integrating rare earth metal and magnet production to create a comprehensive magnet-to-mine supply chain. Production Acceleration: Construction at the Round Top facility in Texas has been advanced, with commercial production now expected by late 2028—two years ahead of the original schedule.